Physician profile
Whitney Cartwright
NPI 1902343304
$2,596.76
in general payments reported to CMS, 2019-2025
22 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $224 · 2022: $1,035 · 2023: $694 · 2024: $443 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,337.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $564.43 | 2022-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $361.03 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $227.13 | 2022-2024 | Evkeeza |
| Amgen INC. | $200.16 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $189.07 | 2021-2024 | Watchman Flx, Watchman Access System, Watchman |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.49 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $145.71 | 2021-2024 | Verquvo |
| Pfizer INC. | $103.29 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $94.86 | 2021-2023 | Camzyos |
| Lilly USA, LLC | $79.50 | 2022 | |
| Novo Nordisk INC | $68.67 | 2024-2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $68.24 | 2021-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $65.89 | 2022-2023 | Xarelto |
| Baxter Healthcare | $49.92 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $39.16 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $35.98 | 2021-2024 | Nexletol |
| Abbvie INC. | $32.09 | 2024 | |
| Irhythm Technologies, INC. | $29.93 | 2023 | Zio Xt Patch |
| Bayer Healthcare Pharmaceuticals INC. | $27.47 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $21.38 | 2024 | Arcalyst |
| Abiomed | $18.43 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Cartwright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.